Alan Tan, MD

home / authors / alan-tan-md

Articles

Two experts are featured in this series.

Opportunities for Guiding Neoadjuvant Treatment Decisions with ctDNA in MIBC

Joshua J. Meeks, MD, PhD, BS;Alan Tan, MD
November 18th 2025

The panelists propose a nuanced view of molecular testing, suggesting ctDNA's value lies in its positive predictive capacity for identifying advanced disease, while utDNA may offer stronger negative predictive insights.

Two experts are featured in this series.

Evaluating ctDNA Biomarkers in MIBC from SunRISe-4

Joshua J. Meeks, MD, PhD, BS;Alan Tan, MD
November 18th 2025

Drs. Meeks and Tan explore the SunRISe-4 trial, highlighting its innovative combination of intravesical therapy and immunotherapy.

Exploratory Analysis of ctDNA in MIBC from CheckMate 274

Exploratory Analysis of ctDNA in MIBC from CheckMate 274

Joshua J. Meeks, MD, PhD, BS;Alan Tan, MD
November 12th 2025

Panelists explore the latest insights on CTDNA in muscle-invasive bladder cancer and its impact on immunotherapy decision-making and patient outcomes.

Two experts are featured in this series.

Challenges in MIBC Management and Opportunities for ctDNA-based Testing

Joshua J. Meeks, MD, PhD, BS;Alan Tan, MD
November 12th 2025

Panelists discuss new findings on adjuvant immunotherapy for high-risk bladder cancer revealing significant insights into patient outcomes and treatment strategies.

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

Episode 14: Multidisciplinary Care Insights Across World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mehmet Asim Bilen, MD;Sid Sadler;Kerry R. Schaffer, MD;Mark T. Fleming, MD;Jeff Yorio, MD;Mike Lattanzi, MD;Elizabeth Kessler, MD;Benjamin L. Maughan, MD, PharmD;Alan Tan, MD
September 18th 2025

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?
Published: November 18th 2025 | Updated: November 21st 2025
How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?